Switch to:
Also traded in: Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 3.69
NAS:REGN's Cash to Debt is ranked lower than
64% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 41.89 vs. NAS:REGN: 3.69 )
Ranked among companies with meaningful Cash to Debt only.
NAS:REGN' s Cash to Debt Range Over the Past 10 Years
Min: 0.58  Med: 1.95 Max: No Debt
Current: 3.69
Equity to Asset 0.66
NAS:REGN's Equity to Asset is ranked lower than
51% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:REGN: 0.66 )
Ranked among companies with meaningful Equity to Asset only.
NAS:REGN' s Equity to Asset Range Over the Past 10 Years
Min: 0.18  Med: 0.55 Max: 0.93
Current: 0.66
0.18
0.93
Interest Coverage 319.61
NAS:REGN's Interest Coverage is ranked lower than
69% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:REGN: 319.61 )
Ranked among companies with meaningful Interest Coverage only.
NAS:REGN' s Interest Coverage Range Over the Past 10 Years
Min: 10.1  Med: 19.03 Max: 319.61
Current: 319.61
10.1
319.61
F-Score: 6
Z-Score: 11.85
M-Score: -2.76
WACC vs ROIC
14.06%
24.56%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 25.67
NAS:REGN's Operating margin (%) is ranked higher than
89% of the 735 Companies
in the Global Biotechnology industry.

( Industry Median: -88.05 vs. NAS:REGN: 25.67 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:REGN' s Operating margin (%) Range Over the Past 10 Years
Min: -169.68  Med: -20.39 Max: 35.3
Current: 25.67
-169.68
35.3
Net-margin (%) 16.52
NAS:REGN's Net-margin (%) is ranked higher than
86% of the 735 Companies
in the Global Biotechnology industry.

( Industry Median: -76.71 vs. NAS:REGN: 16.52 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:REGN' s Net-margin (%) Range Over the Past 10 Years
Min: -161.3  Med: -20.32 Max: 54.43
Current: 16.52
-161.3
54.43
ROE (%) 20.27
NAS:REGN's ROE (%) is ranked higher than
92% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -33.76 vs. NAS:REGN: 20.27 )
Ranked among companies with meaningful ROE (%) only.
NAS:REGN' s ROE (%) Range Over the Past 10 Years
Min: -61.9  Med: -17.27 Max: 86.68
Current: 20.27
-61.9
86.68
ROA (%) 13.15
NAS:REGN's ROA (%) is ranked higher than
93% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: -30.04 vs. NAS:REGN: 13.15 )
Ranked among companies with meaningful ROA (%) only.
NAS:REGN' s ROA (%) Range Over the Past 10 Years
Min: -20.29  Med: -9.4 Max: 44.08
Current: 13.15
-20.29
44.08
ROC (Joel Greenblatt) (%) 42.35
NAS:REGN's ROC (Joel Greenblatt) (%) is ranked higher than
90% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. NAS:REGN: 42.35 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:REGN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -191.59  Med: -33.04 Max: 61.97
Current: 42.35
-191.59
61.97
Revenue Growth (3Y)(%) 43.90
NAS:REGN's Revenue Growth (3Y)(%) is ranked higher than
87% of the 471 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. NAS:REGN: 43.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:REGN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -25  Med: 33.3 Max: 81.1
Current: 43.9
-25
81.1
EBITDA Growth (3Y)(%) 38.40
NAS:REGN's EBITDA Growth (3Y)(%) is ranked higher than
86% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. NAS:REGN: 38.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:REGN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -24.4  Med: 29.85 Max: 83.5
Current: 38.4
-24.4
83.5
EPS Growth (3Y)(%) -6.50
NAS:REGN's EPS Growth (3Y)(%) is ranked lower than
54% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. NAS:REGN: -6.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:REGN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -21.8  Med: -6.15 Max: 86.3
Current: -6.5
-21.8
86.3
GuruFocus has detected 3 Warning Signs with Regeneron Pharmaceuticals Inc $NAS:REGN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:REGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

REGN Guru Trades in Q1 2016

Steven Cohen 109,700 sh (New)
Ray Dalio 900 sh (New)
Jim Simons 216,962 sh (+102.27%)
Vanguard Health Care Fund 3,169,490 sh (+38.98%)
Samuel Isaly 137,000 sh (+23.42%)
Pioneer Investments Sold Out
Paul Tudor Jones Sold Out
Ken Fisher 613 sh (-0.33%)
Mario Gabelli 1,343 sh (-2.54%)
Frank Sands 3,387,921 sh (-8.40%)
Ron Baron 5,011 sh (-32.86%)
Joel Greenblatt 2,525 sh (-39.26%)
» More
Q2 2016

REGN Guru Trades in Q2 2016

Paul Tudor Jones 2,956 sh (New)
Joel Greenblatt 30,151 sh (+1094.10%)
Vanguard Health Care Fund 3,279,190 sh (+3.46%)
Ken Fisher 613 sh (unchged)
Steven Cohen Sold Out
Ray Dalio Sold Out
Ron Baron 4,987 sh (-0.48%)
Mario Gabelli 1,329 sh (-1.04%)
Jim Simons 210,762 sh (-2.86%)
Frank Sands 2,659,741 sh (-21.49%)
Samuel Isaly 108,200 sh (-21.02%)
» More
Q3 2016

REGN Guru Trades in Q3 2016

George Soros 1,381 sh (New)
Paul Tudor Jones 4,608 sh (+55.89%)
Ken Fisher 620 sh (+1.14%)
Vanguard Health Care Fund 3,279,190 sh (unchged)
Jim Simons Sold Out
Ron Baron 4,924 sh (-1.26%)
Frank Sands 2,497,378 sh (-6.10%)
Joel Greenblatt 24,745 sh (-17.93%)
Mario Gabelli 529 sh (-60.20%)
Samuel Isaly 60,662 sh (-43.94%)
» More
Q4 2016

REGN Guru Trades in Q4 2016

Ken Fisher 715 sh (+15.32%)
Spiros Segalas 801,805 sh (-6.81%)
» More
» Details

Insider Trades

Latest Guru Trades with REGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:CSLLY, NAS:ALXN, OTCPK:SHPGF, OTCPK:ALIOY, NAS:INCY, NAS:VRTX, NAS:BIIB, NAS:BMRN, OTCPK:UCBJY, NAS:GRFS, OTCPK:GMXAY, OTCPK:NVZMY, NAS:ALKS, NAS:SGEN, NAS:TSRO, NAS:JAZZ, NAS:UTHR, NAS:IONS, OTCPK:SBMFF, NAS:EXEL » details
Traded in other countries:RGO.Germany, REGN.Mexico, REGN.Switzerland, 0R2M.UK,
Regeneron Pharmaceuticals Inc is a fully integrated biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Regeneron Pharmaceuticals Inc was incorporated in in the State of New York on January 11, 1988. The Company is a biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The Company's preclinical research programs are in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. Its manufacturing facilities are located in Rensselaer, New York and consist of three buildings totaling approximately 490,000 square feet of research, manufacturing, office, and warehouse space. It currently has approximately 74,000liters of cell culture capacity at these facilities. It faces competition from pharmaceutical, biotechnology, and chemical companies. Its competitors are Genentech, Novartis, Pfizer Inc., Bayer HealthCare, Onyx Pharmaceuticals, Inc., Eli Lilly and Company, Abbott, sanofi-aventis, Merck & Co., Amgen Inc., Roche, and others. Its present and future business would be subject to regulation under the United States Atomic Energy Act, the Clean Air Act, the Clean Water Act, the Comprehensive Environmental Response, Compensation and Liability Act, the National Environmental Policy Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act, national restrictions, and other current and potential future local, state, federal, and foreign regulations.

Guru Investment Theses on Regeneron Pharmaceuticals Inc

Baron Funds Comments on Regeneron Pharmaceuticals - May 23, 2016

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) fell in the first quarter as a result of the significant sell-off in the biotech/pharma space and a miss on the top and bottom lines versus the expected fourth quarter results. 2016 guidance for Eylea (its lead ophthalmology asset) was sharply down from 2015. Launch of its new cardiovascular drug, Praluent, has been slow, and it lost a court case involving the drug. We have trimmed our position but decided that Regeneron deserved benefit of the doubt. Given Sanofi’s 22% ownership and its reliance on company for R&D productivity, we believe Regeneron enjoys a privileged position in the biotech universe.



From Baron Fifth Avenue Growth Fund first quarter commentary 2016.



Check out Ron Baron latest stock trades

Top Ranked Articles about Regeneron Pharmaceuticals Inc

Baron Funds Comments on Regeneron Pharmaceuticals Guru stock highlight
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) fell in the first quarter as a result of the significant sell-off in the biotech/pharma space and a miss on the top and bottom lines versus the expected fourth quarter results. 2016 guidance for Eylea (its lead ophthalmology asset) was sharply down from 2015. Launch of its new cardiovascular drug, Praluent, has been slow, and it lost a court case involving the drug. We have trimmed our position but decided that Regeneron deserved benefit of the doubt. Given Sanofi’s 22% ownership and its reliance on company for R&D productivity, we believe Regeneron enjoys a privileged position in the biotech universe. Read more...
Vanguard Boosts Stake in Incyte in 1st Quarter Guru sells holdings in CVS Health, Edwards Lifesciences, Monsanto
Vanguard Health Care Fund continued a streak of double-digit returns in 2015 with returns of 12.65%. That is below the fund’s returns levels of 2014 (28.52%) and 2013 (43.19%), but it is still in double digits, which was a considerable achievement in 2015’s challenging investing environment. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 52.59
REGN's P/E(ttm) is ranked lower than
73% of the 247 Companies
in the Global Biotechnology industry.

( Industry Median: 28.00 vs. REGN: 52.59 )
Ranked among companies with meaningful P/E(ttm) only.
REGN' s P/E(ttm) Range Over the Past 10 Years
Min: 22.84  Med: 76.54 Max: 169.6
Current: 52.59
22.84
169.6
Forward P/E 24.81
REGN's Forward P/E is ranked lower than
60% of the 62 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. REGN: 24.81 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 52.59
REGN's PE(NRI) is ranked lower than
73% of the 245 Companies
in the Global Biotechnology industry.

( Industry Median: 28.16 vs. REGN: 52.59 )
Ranked among companies with meaningful PE(NRI) only.
REGN' s PE(NRI) Range Over the Past 10 Years
Min: 22.84  Med: 76.54 Max: 169.6
Current: 52.59
22.84
169.6
Price/Owner Earnings (ttm) 82.93
REGN's Price/Owner Earnings (ttm) is ranked lower than
77% of the 143 Companies
in the Global Biotechnology industry.

( Industry Median: 30.02 vs. REGN: 82.93 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
REGN' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 49.67  Med: 104.36 Max: 1511.41
Current: 82.93
49.67
1511.41
P/B 8.34
REGN's P/B is ranked lower than
82% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 3.49 vs. REGN: 8.34 )
Ranked among companies with meaningful P/B only.
REGN' s P/B Range Over the Past 10 Years
Min: 2.47  Med: 9.86 Max: 26.41
Current: 8.34
2.47
26.41
P/S 8.67
REGN's P/S is ranked higher than
56% of the 683 Companies
in the Global Biotechnology industry.

( Industry Median: 10.85 vs. REGN: 8.67 )
Ranked among companies with meaningful P/S only.
REGN' s P/S Range Over the Past 10 Years
Min: 3.69  Med: 12.54 Max: 27.67
Current: 8.67
3.69
27.67
PFCF 49.32
REGN's PFCF is ranked lower than
75% of the 126 Companies
in the Global Biotechnology industry.

( Industry Median: 22.44 vs. REGN: 49.32 )
Ranked among companies with meaningful PFCF only.
REGN' s PFCF Range Over the Past 10 Years
Min: 36.13  Med: 103.05 Max: 7496
Current: 49.32
36.13
7496
POCF 29.93
REGN's POCF is ranked lower than
63% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 19.90 vs. REGN: 29.93 )
Ranked among companies with meaningful POCF only.
REGN' s POCF Range Over the Past 10 Years
Min: 21.69  Med: 51.88 Max: 316.18
Current: 29.93
21.69
316.18
EV-to-EBIT 30.19
REGN's EV-to-EBIT is ranked lower than
64% of the 243 Companies
in the Global Biotechnology industry.

( Industry Median: 19.16 vs. REGN: 30.19 )
Ranked among companies with meaningful EV-to-EBIT only.
REGN' s EV-to-EBIT Range Over the Past 10 Years
Min: -108.7  Med: -6.4 Max: 1948.5
Current: 30.19
-108.7
1948.5
EV-to-EBITDA 27.88
REGN's EV-to-EBITDA is ranked lower than
68% of the 266 Companies
in the Global Biotechnology industry.

( Industry Median: 16.65 vs. REGN: 27.88 )
Ranked among companies with meaningful EV-to-EBITDA only.
REGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -141.9  Med: -7.2 Max: 387.4
Current: 27.88
-141.9
387.4
Shiller P/E 217.11
REGN's Shiller P/E is ranked lower than
93% of the 56 Companies
in the Global Biotechnology industry.

( Industry Median: 48.03 vs. REGN: 217.11 )
Ranked among companies with meaningful Shiller P/E only.
REGN' s Shiller P/E Range Over the Past 10 Years
Min: 208.16  Med: 684.92 Max: 4161.1
Current: 217.11
208.16
4161.1
Current Ratio 3.64
REGN's Current Ratio is ranked lower than
55% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. REGN: 3.64 )
Ranked among companies with meaningful Current Ratio only.
REGN' s Current Ratio Range Over the Past 10 Years
Min: 2.55  Med: 6.18 Max: 20.69
Current: 3.64
2.55
20.69
Quick Ratio 3.28
REGN's Quick Ratio is ranked lower than
56% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. REGN: 3.28 )
Ranked among companies with meaningful Quick Ratio only.
REGN' s Quick Ratio Range Over the Past 10 Years
Min: 2.55  Med: 6.04 Max: 20.5
Current: 3.28
2.55
20.5
Days Inventory 303.05
REGN's Days Inventory is ranked lower than
85% of the 439 Companies
in the Global Biotechnology industry.

( Industry Median: 127.64 vs. REGN: 303.05 )
Ranked among companies with meaningful Days Inventory only.
REGN' s Days Inventory Range Over the Past 10 Years
Min: 65.06  Med: 124.08 Max: 780.78
Current: 303.05
65.06
780.78
Days Sales Outstanding 126.81
REGN's Days Sales Outstanding is ranked lower than
80% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 61.83 vs. REGN: 126.81 )
Ranked among companies with meaningful Days Sales Outstanding only.
REGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 23.13  Med: 64.12 Max: 157.07
Current: 126.81
23.13
157.07
Days Payable 135.31
REGN's Days Payable is ranked higher than
77% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 58.15 vs. REGN: 135.31 )
Ranked among companies with meaningful Days Payable only.
REGN' s Days Payable Range Over the Past 10 Years
Min: 131.02  Med: 569.61 Max: 2718.58
Current: 135.31
131.02
2718.58

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.50
REGN's 3-Year Average Share Buyback Ratio is ranked higher than
81% of the 550 Companies
in the Global Biotechnology industry.

( Industry Median: -11.00 vs. REGN: -2.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
REGN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -14.7  Med: -7 Max: -2.5
Current: -2.5
-14.7
-2.5

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 32.13
REGN's Price/Net Current Asset Value is ranked lower than
91% of the 633 Companies
in the Global Biotechnology industry.

( Industry Median: 5.63 vs. REGN: 32.13 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
REGN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 3.34  Med: 10.47 Max: 157.38
Current: 32.13
3.34
157.38
Price/Tangible Book 8.34
REGN's Price/Tangible Book is ranked lower than
74% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.31 vs. REGN: 8.34 )
Ranked among companies with meaningful Price/Tangible Book only.
REGN' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.54  Med: 5.63 Max: 22
Current: 8.34
1.54
22
Price/Projected FCF 5.07
REGN's Price/Projected FCF is ranked lower than
65% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 2.87 vs. REGN: 5.07 )
Ranked among companies with meaningful Price/Projected FCF only.
REGN' s Price/Projected FCF Range Over the Past 10 Years
Min: 5.07  Med: 16.26 Max: 206.31
Current: 5.07
5.07
206.31
Price/Median PS Value 0.69
REGN's Price/Median PS Value is ranked higher than
70% of the 593 Companies
in the Global Biotechnology industry.

( Industry Median: 0.94 vs. REGN: 0.69 )
Ranked among companies with meaningful Price/Median PS Value only.
REGN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.18  Med: 0.99 Max: 4.22
Current: 0.69
0.18
4.22
Price/Graham Number 4.42
REGN's Price/Graham Number is ranked lower than
76% of the 197 Companies
in the Global Biotechnology industry.

( Industry Median: 2.37 vs. REGN: 4.42 )
Ranked among companies with meaningful Price/Graham Number only.
REGN' s Price/Graham Number Range Over the Past 10 Years
Min: 1.33  Med: 6.61 Max: 10.19
Current: 4.42
1.33
10.19
Earnings Yield (Greenblatt) (%) 3.26
REGN's Earnings Yield (Greenblatt) (%) is ranked higher than
83% of the 924 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. REGN: 3.26 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
REGN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 2.3 Max: 24.9
Current: 3.26
0.1
24.9

More Statistics

Revenue (TTM) (Mil) $4,732
EPS (TTM) $ 6.75
Beta1.57
Short Percentage of Float3.54%
52-Week Range $325.35 - 484.57
Shares Outstanding (Mil)105.47

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 4,908 5,673 6,328 7,102
EPS ($) 11.39 14.88 17.21 20.33
EPS w/o NRI ($) 11.39 14.88 17.21 20.33
EPS Growth Rate
(3Y to 5Y Estimate)
15.03%
Dividends Per Share ($)
» More Articles for REGN

Headlines

Articles On GuruFocus.com
A Green Light on Bayer Jan 19 2017 
Largest Insider Trades of the Week Jan 16 2017 
Take a Look at Sanofi Oct 05 2016 
3 of Frank Sands' Top 5 Transactions in 2nd Quarter Were Reductions Aug 14 2016 
Edward Owens Top 2nd Quarter Investments Aug 03 2016 
Frank Sands Sells Visa, Baidu, Alibaba May 24 2016 
Baron Funds Comments on Regeneron Pharmaceuticals May 23 2016 
Market-Beating Vanguard Health Care Fund Adds Shares to 5 Positions May 03 2016 
Vanguard Boosts Stake in Incyte in 1st Quarter May 02 2016 
Amgen: Should I Just Sit and Wait? Mar 18 2016 

More From Other Websites
Failed Mergers Cast Shadow on Sanofi's Future Jan 23 2017
Regeneron Pharmaceuticals Could Be Ready to Rebound Jan 20 2017
These Insiders Are Still Finding Some Good Value in the Stock Market Jan 19 2017
Regeneron, Sanofi Claim Amgen's LDL-Buster Patent Too Broad Jan 17 2017
Key FDA Events to Watch Out for in Q1 Jan 17 2017
Odds Are Against Regeneron, Sanofi In Amgen Patent Battle: Leerink Jan 13 2017
Regeneron, Sanofi's Drug Manufacturing Plant Cleared Jan 12 2017
Merrill Lynch Has 4 Red-Hot Stocks to Buy With Up to 75% Upside Potential Jan 12 2017
Trump's Comments Are Big Pharma's Nightmare Jan 11 2017
Trump's Comments Are Big Pharma's Nightmare Jan 11 2017
Todd Hagopian's Top Biotech Takeover Targets For 2017 Jan 10 2017
Regeneron CEO: The industry doesn't put patients first Jan 10 2017
The Zacks Analyst Blog Highlights: Clovis Oncology, Pfizer, Roche's, Sanofi and Regeneron... Jan 10 2017
Amgen Inks Multiple Deals, Offers Update on Repatha Lawsuit Jan 10 2017
Regeneron CEO says Amgen not putting patients first in patent dispute Jan 09 2017
Regeneron CEO says Amgen not putting patients first in patent dispute Jan 09 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)